Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-31 6:43 pm Purchase | 2025-01-24 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BIOTECHNOLOGY VALUE FUND L P | 4,393,210 7.200% | 4,393,210 (New Position) | Filing History |
| 2025-01-29 5:12 pm Sale | 2025-01-27 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND L P | 945,402 1.800% | -2,106,037 (-69.02%) | Filing History |
| 2025-01-29 5:09 pm Sale | 2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN | BIOTECHNOLOGY VALUE FUND L P | 3,051,439 5.900% | -145,000 (-4.54%) | Filing History |
| 2025-01-28 5:19 pm Sale | 2025-01-24 | 13D | XOMA Corporation XOMA | BIOTECHNOLOGY VALUE FUND L P | 2,983,026 25.300% | -650,717 (-17.91%) | Filing History |
| 2025-01-06 6:38 pm Purchase | 2024-12-27 | 13G | RAPT Therapeutics, Inc. RAPT | BIOTECHNOLOGY VALUE FUND L P | 11,764,000 8.700% | 11,764,000 (New Position) | Filing History |
| 2024-12-23 9:25 pm Unchanged | 2024-12-19 | 13D | Inventiva S.A. IVA | BIOTECHNOLOGY VALUE FUND L P | 8,545,499 9.000% | 0 (Unchanged) | Filing History |
| 2024-12-17 5:42 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND L P | 1,168,117 9.990% | 1,168,117 (New Position) | Filing History |
| 2024-12-04 7:49 pm Sale | 2024-12-04 | 13D | Olema Pharmaceuticals, Inc. OLMA | BIOTECHNOLOGY VALUE FUND L P | 7,557,237 9.990% | -1,578,656 (-17.28%) | Filing History |
| 2024-11-21 8:27 pm Purchase | 2024-11-14 | 13G | iTeos Therapeutics, Inc. ITOS | BIOTECHNOLOGY VALUE FUND L P | 2,325,000 6.400% | 1,065,524 (+84.60%) | Filing History |
| 2024-11-18 5:23 pm Purchase | 2024-11-11 | 13G | Verve Therapeutics, Inc. VERV | BIOTECHNOLOGY VALUE FUND L P | 6,904,050 8.200% | 6,904,050 (New Position) | Filing History |
| 2024-11-14 4:40 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% | 658,093 (+14.91%) | Filing History |
| 2024-11-14 4:39 pm Sale | 2024-09-30 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 3,853,818 5.400% | -2,997,233 (-43.75%) | Filing History |
| 2024-11-14 4:38 pm Purchase | 2024-09-30 | 13G | Verastem, Inc. VSTM | BIOTECHNOLOGY VALUE FUND L P | 4,279,521 9.990% | 1,662,119 (+63.50%) | Filing History |
| 2024-11-14 4:37 pm Purchase | 2024-09-30 | 13G | Molecular Templates, Inc. MTEM | BIOTECHNOLOGY VALUE FUND L P | 672,767 9.990% | 135,341 (+25.18%) | Filing History |
| 2024-11-14 4:37 pm Sale | 2024-09-30 | 13G | Mirum Pharmaceuticals, Inc. MIRM | BIOTECHNOLOGY VALUE FUND L P | 3,075,907 6.400% | -1,294,117 (-29.61%) | Filing History |
| 2024-11-14 4:36 pm Purchase | 2024-09-30 | 13G | Annexon, Inc. ANNX | BIOTECHNOLOGY VALUE FUND L P | 9,027,778 8.400% | 2,027,778 (+28.97%) | Filing History |
| 2024-11-14 4:36 pm Purchase | 2024-09-30 | 13G | AC Immune SA ACIU | BIOTECHNOLOGY VALUE FUND L P | 19,522,436 19.700% | 4,951,200 (+33.98%) | Filing History |
| 2024-11-14 4:34 pm Purchase | 2024-09-30 | 13G | Tyra Biosciences, Inc. TYRA | BIOTECHNOLOGY VALUE FUND L P | 4,661,194 8.800% | 1,921,599 (+70.14%) | Filing History |
| 2024-11-14 4:33 pm Sale | 2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,833,785 (Position Closed) | Filing History |
| 2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 4,212,346 5.400% | -3,160,882 (-42.87%) | Filing History |